| Secondary |
| Product Used For Unknown Indication |
44.2% |
| Drug Use For Unknown Indication |
22.4% |
| Hypertension |
4.4% |
| Myocardial Infarction |
3.3% |
| Diabetes Mellitus |
2.8% |
| Heart Transplant |
2.5% |
| Eye Infection Toxoplasmal |
2.2% |
| Renal Transplant |
2.2% |
| Wound Infection |
2.2% |
| Thrombophlebitis |
1.9% |
| Atrial Fibrillation |
1.7% |
| Listeria Encephalitis |
1.7% |
| Hypokalaemia |
1.4% |
| Insulin-requiring Type 2 Diabetes Mellitus |
1.4% |
| Hypertension Arterial |
1.1% |
| Lupus-like Syndrome |
1.1% |
| Osteoarthritis |
1.1% |
| Anxiety |
0.8% |
| Gout |
0.8% |
| Transplant Rejection |
0.8% |
|
| Renal Failure Acute |
24.2% |
| Renal Failure |
12.9% |
| Myoglobin Blood Increased |
11.3% |
| Lymphopenia |
6.5% |
| Aphthous Stomatitis |
4.8% |
| Nausea |
4.8% |
| Urinary Tract Infection |
4.8% |
| Hepatitis B |
3.2% |
| Hyperkalaemia |
3.2% |
| Lung Infiltration |
3.2% |
| Oesophagitis |
3.2% |
| Thrombocytopenic Purpura |
3.2% |
| Weight Increased |
3.2% |
| Anaphylactic Shock |
1.6% |
| Clostridium Difficile Colitis |
1.6% |
| Dyskinesia |
1.6% |
| Eczema |
1.6% |
| Haemolytic Anaemia |
1.6% |
| Hypokalaemia |
1.6% |
| Hyponatraemia |
1.6% |
|
| Concomitant |
| Product Used For Unknown Indication |
28.7% |
| Drug Use For Unknown Indication |
18.4% |
| Hypertension |
11.4% |
| Atrial Fibrillation |
5.1% |
| Rheumatoid Arthritis |
4.7% |
| Pain |
4.6% |
| Prophylaxis |
3.8% |
| Hypokalaemia |
2.8% |
| Mineral Supplementation |
2.1% |
| Acute Myocardial Infarction |
2.1% |
| Dyspnoea |
2.0% |
| Depression |
1.9% |
| Type 2 Diabetes Mellitus |
1.8% |
| Hypercholesterolaemia |
1.7% |
| Cardiac Failure |
1.6% |
| Diabetes Mellitus |
1.5% |
| Diuretic Therapy |
1.5% |
| Anxiety |
1.5% |
| Hypothyroidism |
1.4% |
| Nausea |
1.4% |
|
| Renal Failure Acute |
14.2% |
| Vomiting |
10.4% |
| Thrombocytopenia |
9.5% |
| Renal Failure |
6.6% |
| Vertigo |
5.7% |
| Pyrexia |
5.2% |
| Weight Decreased |
5.2% |
| Pain In Extremity |
4.3% |
| Shock Haemorrhagic |
3.8% |
| Tremor |
3.8% |
| Interstitial Lung Disease |
3.3% |
| Myocardial Infarction |
3.3% |
| Pruritus |
3.3% |
| Pulmonary Embolism |
3.3% |
| Pulmonary Hypertension |
3.3% |
| Vasculitis |
3.3% |
| Anaemia |
2.8% |
| Drug Interaction |
2.8% |
| International Normalised Ratio Increased |
2.8% |
| Nephrogenic Systemic Fibrosis |
2.8% |
|
| Interacting |
| Drug Use For Unknown Indication |
55.6% |
| Product Used For Unknown Indication |
22.2% |
| Essential Hypertension |
5.6% |
| Hepatosplenic Candidiasis |
5.6% |
| Hypertension |
5.6% |
| Hypothyroidism |
5.6% |
|
| Renal Failure Acute |
42.9% |
| Syncope |
28.6% |
| Hyperkalaemia |
14.3% |
| Sinoatrial Block |
14.3% |
|
